Physician profile
Michael Black
NPI 1588892194
$3,455.10
in general payments reported to CMS, 2019-2025
37 companies · $729 in 2025
The $729 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $164 · 2021: $175 · 2022: $466 · 2023: $616 · 2024: $600 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,945.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $793.64 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $404.90 | 2019-2025 | Breztri, Airsupra |
| Pfizer INC. | $275.34 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $255.49 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $161.94 | 2022-2025 | Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.76 | 2019-2024 | Jardiance |
| Amgen INC. | $153.80 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $151.62 | 2023-2025 | Jardiance, Emgality, Zepbound |
| Novo Nordisk INC | $144.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Daiichi Sankyo INC. | $113.50 | 2019 | |
| Glaxosmithkline, LLC. | $105.45 | 2019-2020 | |
| Amarin Pharma, INC. | $57.32 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $57.21 | 2023-2025 | Nuzyra, Xhance |
| Merck Sharp & Dohme LLC | $55.60 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Mylan Specialty L.P. | $55.36 | 2023-2024 | Yupelri |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $50.08 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $40.92 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $36.36 | 2024-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $34.32 | 2024 | Voquezna |
| Dexcom, INC. | $32.49 | 2023 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $26.98 | 2024 | Inspire |
| Abbott Laboratories | $25.60 | 2021-2022 | |
| Tonix Medicines, INC. | $25.24 | 2025 | Tonmya |
| Horizon Therapeutics Plc | $24.98 | 2021 | |
| Verona Pharma, INC. | $23.30 | 2025 | Ohtuvayre |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.59 | 2025 | Caplyta |
| Astellas Pharma US INC | $21.10 | 2025 | Veozah |
| Tris Pharma INC | $19.74 | 2024 | Dyanavel Xr |
| Allergan, INC. | $17.30 | 2019 | |
| Grt US Holding, INC. | $16.99 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.34 | 2023 | |
| Medtronic USA, INC. | $15.34 | 2019 | |
| Bioventus LLC | $14.83 | 2019 | |
| Ucb, INC. | $13.34 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.47 | 2019 | |
| Neos Therapeutics, Lp | $11.24 | 2021 | |
| Axsome Therapeutics, INC. | $11.14 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.